dc.creator | Vieira, Sabas Carlos | |
dc.creator | Zeferino, Luiz Carlos | |
dc.creator | Da Silva, Benedito Borges | |
dc.creator | Aparecida Pinto, Glauce | |
dc.creator | Vassallo, José | |
dc.creator | Carasan, Gislaine Aparecida Fonsechi | |
dc.creator | De Moraes, Natália Guimarães | |
dc.date | 2004-Apr | |
dc.date | 2015-11-27T12:58:50Z | |
dc.date | 2015-11-27T12:58:50Z | |
dc.date.accessioned | 2018-03-29T01:00:29Z | |
dc.date.available | 2018-03-29T01:00:29Z | |
dc.identifier | Gynecologic Oncology. v. 93, n. 1, p. 121-4, 2004-Apr. | |
dc.identifier | 0090-8258 | |
dc.identifier | 10.1016/j.ygyno.2004.01.033 | |
dc.identifier | http://www.ncbi.nlm.nih.gov/pubmed/15047224 | |
dc.identifier | http://repositorio.unicamp.br/jspui/handle/REPOSIP/196176 | |
dc.identifier | 15047224 | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/1296409 | |
dc.description | The aim of this study was to evaluate the quantification of angiogenesis by assessing microvessel density in cervical cancer, comparing the performance of three monoclonal antibodies: anti-CD34 and BNH9, which are still little known markers in cervical neoplasia, and anti-CD31. Fifty-four consecutive patients diagnosed with stages I and II invasive cervical cancer undergoing radical hysterectomy and bilateral pelvic lymphadenectomy were evaluated. The monoclonal primary antibodies used were anti-CD34, anti-CD31 and BNH9 antibody. The areas of highest microvessel density were used for counting microvessels in 10 high-power fields. Microvessel density was the mean vessel number counted in 10 high-power fields. The mean of microvessel density was 10.3, 9.7 and 5.8 for anti-CD34, BNH9 and anti-CD31, respectively. According to the Kruskal-Wallis nonparametric test, microvessel density estimated by anti-CD34 and BNH9 was significantly higher than the microvessel density estimated by anti-CD31. The difference between microvessel density measured by anti-CD34 and BNH9 was not statistically significant. There was diagnostic agreement in 44 out of 54 cases for anti-CD34 and BNH9 monoclonal antibodies, kappa coefficient being 0.63. The kappa coefficient was 0.41 between anti-CD34 and anti-CD31 and 0.26 between anti-CD31 and BNH9. The anti-CD34 and BNH9 seem to have higher sensitivity than anti-CD31. The agreement to quantify microvessel density between anti-CD34 and BNH9 is higher than between them and anti-CD31. Additionally, considering that the BNH9 is much less unknown than anti-CD34 and that they showed very similar performance, the BNH9 clinical significance should be test in different neoplasms. | |
dc.description | 93 | |
dc.description | 121-4 | |
dc.language | eng | |
dc.relation | Gynecologic Oncology | |
dc.relation | Gynecol. Oncol. | |
dc.rights | fechado | |
dc.rights | | |
dc.source | PubMed | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Antibodies, Monoclonal | |
dc.subject | Antigens, Cd31 | |
dc.subject | Antigens, Cd34 | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Immunohistochemistry | |
dc.subject | Middle Aged | |
dc.subject | Neoplasm Staging | |
dc.subject | Neovascularization, Pathologic | |
dc.subject | Uterine Cervical Neoplasms | |
dc.title | Quantification Of Angiogenesis In Cervical Cancer: A Comparison Among Three Endothelial Cell Markers. | |
dc.type | Artículos de revistas | |